Nanovibronix (NASDAQ:FEED – Get Free Report) is one of 28 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its peers? We will compare Nanovibronix to related companies based on the strength of its risk, analyst recommendations, earnings, profitability, valuation, dividends and institutional ownership.
Volatility and Risk
Nanovibronix has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Nanovibronix’s peers have a beta of 1.76, suggesting that their average share price is 76% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Nanovibronix and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Nanovibronix Competitors | 77 | 76 | 156 | 6 | 2.29 |
Institutional and Insider Ownership
16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 1.4% of Nanovibronix shares are owned by company insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Nanovibronix and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
| Nanovibronix Competitors | -672.41% | -133.75% | -59.01% |
Valuation & Earnings
This table compares Nanovibronix and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Nanovibronix | $2.56 million | -$3.70 million | -0.07 |
| Nanovibronix Competitors | $57.98 million | -$32.15 million | 4.18 |
Nanovibronix’s peers have higher revenue, but lower earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
Nanovibronix peers beat Nanovibronix on 8 of the 13 factors compared.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
